



Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: Effects on HDAC biology and antiproliferative activity

Subhasish Tapadar^a, Rong He^a, Doris N. Luchini^b, Daniel D. Billadeau^b, Alan P. Kozikowski^{a,*}

^a Department of Medicinal Chemistry & Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street Chicago, IL 60612, USA

^b Division of Oncology Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA

ARTICLE INFO

Article history:

Received 22 January 2009

Revised 4 April 2009

Accepted 7 April 2009

Available online 20 April 2009

Keywords:

HDAC

Pancreatic cancer

HDAC inhibitor

Isoform

ABSTRACT

A series of hydroxamic acid based histone deacetylase inhibitors **6–15**, containing an isoxazole moiety adjacent to the Zn-chelating hydroxamic acid, is reported herein. Some of these compounds showed nanomolar activity in the HDAC isoform inhibitory assay and exhibited micro molar inhibitory activity against five pancreatic cancer cell lines.

© 2009 Elsevier Ltd. All rights reserved.


Epigenetic regulation of gene expression is partly controlled by chromatin remodeling which is initiated either by post-translational modification of histone proteins^{1,2} or DNA methylation.³ Several different modifications that occur in histone amino termini are defined as acetylation, methylation, ubiquitinylation, and glycosylation. Histone acetylation–deacetylation is a reversible phenomenon and is tightly regulated by two competing enzymes known as histone acetyltransferases (HATs) and histone deacetylases (HDACs).⁴ In general, HATs catalyse the acetylation of N-terminal lysine ε-amino groups in nuclear histones, resulting in neutralization of the positive charges on the histones and a more open, transcriptionally active chromatin structure while the HDACs catalyze the reverse reaction and suppress transcription. Altered HDAC activity is seen to be associated with many cancers, validating HDACs as promising targets for cancer therapy. Several small molecule HDAC inhibitors^{5–7} (Fig. 1) such as suberoylanilide hydroxamic acid (SAHA), depsipeptide FK228, MS-275, and valproic acid have been found to have promising antitumor activities in clinical studies and in 2006, the US FDA approved SAHA for the treatment of a rare cancer, cutaneous T-cell lymphoma (CTCL).⁸ These compounds owe their antiproliferative action to their ability to allow the transcription and expression of repressed genes including tumor suppressor genes. Beside their antitumor activity, HDAC inhibitors are also found to have potential applications in the treatment of neurodegenerative disorders such as Parkinson's and Huntington's diseases, as well as malaria.⁹ Human HDACs

are divided into four classes based on their function and structural homology. Class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9 and 10), and class IV (HDAC11) HDACs are zinc-dependent enzymes while class III HDACs are sirtuin related proteins and require the cofactor NAD⁺ for their deacetylase function.⁷ To learn more about the role the individual HDACs play in cell growth and differentiation, neuronal protection, and apoptosis, it is important to develop agents that show selectivity for individual isoforms or a small subset of these isoforms. To date, a large number of structurally diverse, natural and synthetic, hydroxamic acid based HDAC inhibitors (Fig. 1) have been reported which include trichostatin A (TSA), SAHA, depsipeptide, and tubacin, but the number of isoform selective HDAC inhibitors are very limited.^{5,6} Recently, we have reported hydroxamate-based HDAC inhibitors bearing substituted aryl-isoxazoles (Fig. 2) as the cap groups. Some of these compounds were found to be highly potent and selective at HDAC6 as well as HDAC3 (compound **1** and **2**, Table 1).¹⁰


We anticipated that the exceptional potency and selectivity of those compounds were due to the presence of the isoxazole moiety whose mode of interaction with surface residues is still under investigation. In this Letter, we report a series of hydroxamic acid-based HDAC inhibitors with an isoxazole moiety in the linker region adjacent to the hydroxamic acid group (Fig. 3). These compounds were designed with the idea that the more rigid and bulkier zinc binding group might allow for a different selectivity. The choice of the cap groups was based on the HDAC inhibitors previously explored by us^{11,12} (Fig. 2, Table 1) and Miyata et al.¹³ In this context, the hydroxamic acid was suitably replaced by the other functionalities like alcohol, carboxylic acid, and amide to explore

* Corresponding author. Tel.: +1 312 996 7577.


E-mail address: kozikowa@uic.edu (A.P. Kozikowski).



Scheme 1. Synthesis of compounds **6–10**. Reagents and conditions: (a) 7-Heptynoic acid, POCl₃, pyridine, –13 °C to rt, 30 min; (b) ethyl chlorooxamidoacetate, triethylamine, THF, rt, 16 h; (c) H₂, 10% Pd/C, EtOAc, EtOH, 60 °C, 30 min; (d) NH₂OH·HCl, KOH, MeOH, rt, 15 min; (e) NaBH₄, MeOH, 0 °C to rt, 2 h; (f) LiOH, THF/MeOH/H₂O (3:1:1), 0 °C, 30 min; (g) ethyl chloroformate, triethylamine, THF, 0 °C, 30 min, then aqueous NH₃, rt, 12 h.



Scheme 2. Synthesis of compounds **11–14**. Reagents and conditions: (a) 7-Heptynoic acid, POCl₃, pyridine, –13 °C to rt, 30 min; (b) ethyl chlorooxamidoacetate, Et₃N, THF, rt, 16 h; (c) NH₂OH·HCl, KOH, MeOH, rt, 15 min; (d) EDCI, HOBT, DIEA, amine, DMF, 0 °C to rt, 12 h.



Scheme 3. Synthesis of compound **15**. Reagents and conditions: (a) LiOH, THF/MeOH/H₂O (3:1:1), 0 °C, 30 min; (b) EDCI, HOBT, DIEA, glycine ethyl ester hydrochloride, DMF, 0 °C to rt, 12 h; (c) LiOH, THF/MeOH/H₂O (3:1:1), 0 °C, 30 min; (d) TFA, CH₂Cl₂, 0 °C to rt, 2 h; (e) **37**, POCl₃, pyridine, –13 °C to rt, 30 min; (f) NH₂OH·HCl, KOH, MeOH, rt, 15 min.

Table 2

In vitro HDAC inhibitory assay results for compounds **6–15**

Compsds	IC ₅₀ (nM)				
	HDAC1	HDAC2	HDAC3	HDAC6	HDAC10
6	303 ± 22	430 ± 37	30 ± 1	68 ± 5	254 ± 25
7	139 ± 4	164 ± 4	25 ± 1	82 ± 5	250 ± 6
8	>30,000	>30,000	>30,000	>30,000	>30,000
9	>30,000	>30,000	10,600 ± 829	>30,000	>30,000
10	>30,000	>30,000	>30,000	>30,000	>30,000
11	328 ± 10	469 ± 18	102 ± 3	51 ± 0.9	471 ± 20
12	885	3,750	7410	885	ND ^a
13	17,100	>30,000	ND ^a	17,100	ND ^a
14	12,300	>30,000	>30,000	12,300	ND ^a
15	9200 ± 670	>30,000	1920 ± 73	1710 ± 82	13,300 ± 560
SAHA^b	96	282	17	14	72

^a ND = not detected.

^b SAHA data provided by Amphora Inc.

Table 3

In vitro growth inhibition assay results against pancreatic cancer cell lines for compounds **6–15**

Compsds	IC ₅₀ (μM)				
	BxPC-3	HupT3	Mia Paca-2	Panc 04.03	Su.86.86
6	3	1	4	4	1
7	10.5	28.4	9	14.4	15
8	>50	>50	>50	>50	>50
9	>50	>50	>50	>50	>50
10	>50	>50	>50	>50	>50
11	36	49	24	44	25
12	9	7	30	>50	9
13	>50	>50	24	30	43
14	>50	>50	>50	>50	>50
15	>50	>50	>50	>50	>50
SAHA	5	0.8	1	1	1

gemcitabine,¹⁹ and thus there is an urgent need for more efficient drugs. All HDAC inhibitors **6–15**, along with the currently marketed drug SAHA were tested on five pancreatic cancer cell lines using the MTT assay. These data are provided in the Table 3. As is apparent from these data, compound **6** nicely inhibited all the five transformed cell lines and its IC₅₀ values were similar to those of SAHA. The relatively weak HDAC inhibitor **12** showed only moderate activity against three of the five transformed cell lines, namely, BxPC-3, HuPT3 and Su.86.86. In contrast, the most potent HDAC inhibitor in this series, compound **7**, only moderately inhibited the five pancreatic cancer cell lines. Compound **11** failed to show similar antiproliferative activity compared to compound **6**, although its IC₅₀ values in the in vitro HDAC inhibitory assay are very similar to those of **6**. The weak inhibitory activities of compound **7** and **11** against different pancreatic cancer cell lines might be due to their poor cell permeability. Compounds **8–10** and **13–15** exhibited poor antiproliferative activities against all five pancreatic cancer cell lines, which are consistent with their poor HDAC inhibitory activities.

In summary, we synthesized a series of hydroxamic acid based HDAC inhibitors wherein the isoxazole moiety was embedded in the linker region and directly attached to the Zn-chelating hydroxamic acid group. The present findings suggest that no significant isozyme selectivity is gained using the more rigid isoxazole hydroxamate as zinc binding group.

Acknowledgement

This work was supported in part by gift funds from an anonymous donor, by a Grant (No. 271210) from the ADDF/Elan, and

by the Mayo Foundation and the Pancreatic Cancer SPOR P50 CA102701.

References and notes

1. Grunstein, M. *Nature* **1997**, 389, 349.
2. Wolffe, A. P.; Guschin, D. J. *Struct. Biol.* **2000**, 129, 102.
3. Abreu, P. A.; Dellamora-Ortiz, G.; Leao-Ferreira, L. R.; Gouveia, M.; Braggio, E.; Zalcberg, I.; Santos, D. O.; Bourguignon, S.; Cabral, L. M.; Rodrigues, C. R.; Castro, H. C. *Exp. Opin. Ther. Targets* **2008**, 12, 1035.
4. Marks, P. A.; Richon, V. M.; Rifkind, R. A. *J. Natl. Cancer Inst.* **2000**, 92, 1210.
5. Butler, K. V.; Kozikowski, A. P. *Curr. Pharm. Des.* **2008**, 14, 505.
6. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. J. *Med. Chem.* **2008**, 51, 1505.
7. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. *Nat. Rev. Drug Disc.* **2006**, 5, 769.
8. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. *Oncologist* **2007**, 12, 1247.
9. Morrison, B. E.; Majdzadeh, N.; Zhang, X.; Lyles, A.; Bassel-Duby, R.; Olson, E. N.; D'Mello, S. R. *Mol. Cell Biol.* **2006**, 26, 3550.
10. Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. *J. Med. Chem.* **2008**, 51, 4370.
11. Kozikowski, A. P.; Chen, Y.; Gaysin, A. M.; Savoy, D. N.; Billadeau, D. D.; Kim, K. H. *ChemMedChem* **2008**, 3, 487.
12. Chen, B.; Petukhov, P. A.; Jung, M.; Velena, A.; Eliseeva, E.; Dritschilo, A.; Kozikowski, A. P. *Bioorg. Med. Chem. Lett.* **2005**, 15, 1389.
13. Itoh, Y.; Suzuki, T.; Kouketsu, A.; Suzuki, N.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. *J. Med. Chem.* **2007**, 50, 5425.
14. Simoni, D.; Invidiata, F. P.; Rondanin, R.; Grimaudo, S.; Cannizzo, G.; Barbusca, E.; Porretto, F.; D'Alessandro, N.; Tolomeo, M. *J. Med. Chem.* **1999**, 42, 4961.
15. Gediya, L. K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.; Njar, V. C. *J. Med. Chem.* **2005**, 48, 5047.
16. Wahhab, A.; Smil, D.; Ajamian, A.; Allan, M.; Chantigny, Y.; Therrien, E.; Nguyen, N.; Manku, S.; Leit, S.; Rahil, J.; Petschner, A. J.; Lu, A. H.; Nicolescu, A.; Lefebvre, S.; Montcalm, S.; Fournel, M.; Yan, T. P.; Li, Z.; Besterman, J. M.; Deziel, R. *Bioorg. Med. Chem. Lett.* **2009**, 19, 336.
17. Hanessian, S.; Vinci, V.; Auzzas, L.; Marzi, M.; Giannini, G. *Bioorg. Med. Chem. Lett.* **2006**, 16, 4784.
18. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. *Lancet* **2004**, 363, 1049.
19. Haller, D. G. *Semin. Oncol.* **2003**, 30, 3.